Loading…
Factors associated with improvement in MELD score after antiviral treatment in patients with chronic hepatitis B
Background and Aims Improvement in Model for End‐Stage Liver Disease (MELD) score during antiviral treatment is associated with reduced hepatic decompensation and death in patients with chronic hepatitis B (CHB)‐related cirrhosis. We aimed to identify factors associated with transplant‐free survival...
Saved in:
Published in: | Journal of gastroenterology and hepatology 2020-09, Vol.35 (9), p.1610-1618 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Background and Aims
Improvement in Model for End‐Stage Liver Disease (MELD) score during antiviral treatment is associated with reduced hepatic decompensation and death in patients with chronic hepatitis B (CHB)‐related cirrhosis. We aimed to identify factors associated with transplant‐free survival and on‐treatment MELD score improvement.
Methods
We identified patients with CHB‐related cirrhosis and MELD score ≥ 15 at the start of entecavir and/or tenofovir disoproxil fumarate treatment between 2005 and 2017. The primary endpoint was transplant‐free survival at month 6. The secondary endpoints at month 6 were transplant‐free survival with > 5‐point improvement in MELD score and transplant‐free survival with MELD score 5‐point improvement in MELD score; 183 (30.2%) had 1‐point to 5‐point improvement in MELD score; 146 (24.1%) had no improvement or a worsened MELD score. Also, 321 (53.1%) patients with transplant‐free survival had a MELD score |
---|---|
ISSN: | 0815-9319 1440-1746 |
DOI: | 10.1111/jgh.15007 |